Search results for "Large B-Cell"

showing 10 items of 69 documents

Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci.

2015

Autoimmune conditions and immune system-related genetic variations are associated with risk of non-Hodgkin lymphoma (NHL). In a pooled analysis of 8,692 NHL cases and 9,260 controls from 14 studies (1988-2007) within the International Lymphoma Epidemiology Consortium, we evaluated the interaction between immune system genetic variants and autoimmune conditions in NHL risk. We evaluated the immunity-related single nucleotide polymorphisms rs1800629 (tumor necrosis factor gene (TNF) G308A), rs1800890 (interleukin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561 (HLA class II), and rs2647012 (HLA class II)) and categorized autoimmune conditions as prim…

LymphomaEpidemiologyOriginal Contributionstumor necrosis factorFollicular lymphomaNon-HodgkininteractionSingle-nucleotide polymorphismHuman leukocyte antigenmedicine.disease_causePolymorphism Single NucleotideAutoimmune DiseaseMedical and Health SciencesMathematical SciencesAutoimmunityAutoimmune DiseasesRare Diseasesimmune system diseasesHLA Antigenshuman leukocyte antigenhemic and lymphatic diseasesGenotypemedicineGeneticsHumans2.1 Biological and endogenous factorsPolymorphismAetiologyCancerbusiness.industryTumor Necrosis Factor-alphaLymphoma Non-HodgkinInflammatory and immune systemautoimmune conditionsOdds ratioSingle NucleotideHematologymedicine.diseaseAutoimmune conditions - risk of non-Hodgkin lymphoma (NHL)LymphomaInterleukin-10Case-Control StudiesImmunologyHIV/AIDSbusinessDiffuse large B-cell lymphomaenvironment
researchProduct

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types

2015

BACKGROUND: Studies of related individuals have consistently demonstrated notable familial aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms (SNPs) for cancer at 13 anatomical sites.METHODS: Between 2007 and 2014, the US National Cancer Institute has generated data from genome-wide association studies (GWAS) for 49 492 cancer case patients and 34 131 control patients. We apply novel mixed model methodology (GCTA) to this GWAS data to estimate the heritability of individual cancers, as well as the proportion of heritability attributable to cigarette smoking in smoking-related cance…

MaleCancer ResearchLung NeoplasmsLymphomaGenome-wide association studyPolymorphism (computer science)NeoplasmsMedicineChronicGeneticsOsteosarcomaOncology And CarcinogenesisLeukemiaSmokingFamily aggregationSingle NucleotideMiddle AgedFamilial riskDiffuseKidney NeoplasmsLymphocyticOncologyAdult; Aged; Asian Continental Ancestry Group; Bone Neoplasms; European Continental Ancestry Group; Female; Humans; Kidney Neoplasms; Leukemia Lymphocytic Chronic B-Cell; Lung Neoplasms; Lymphoma Large B-Cell Diffuse; Male; Middle Aged; Neoplasms; Osteosarcoma; Polymorphism Single Nucleotide; Smoking; Testicular Neoplasms; Tissue Array Analysis; Urinary Bladder Neoplasms; Genetic Predisposition to Disease; Genome-Wide Association StudyFemaleLymphoma Large B-Cell DiffuseAdultAsian Continental Ancestry GroupEuropean Continental Ancestry Group/Bone NeoplasmsPolymorphism Single NucleotideGenetic correlationTesticular NeoplasmsLarge B-CellHumansGenetic Predisposition to DiseaseOncology & CarcinogenesisPolymorphismAgedbusiness.industryExtramuralB-CellCancerHeritabilityGenome-wide association studies for thirteen cancer typesmedicine.diseaseLeukemia Lymphocytic Chronic B-CellUrinary Bladder NeoplasmsTissue Array AnalysisbusinessGenome-Wide Association StudyJournal of the National Cancer Institute
researchProduct

Uncommon Presentations of Non-Hodgkin’s Lymphoma

2003

MaleCancer ResearchPathologymedicine.medical_specialtyLymphoma B-CellProstate biopsyBiopsyDiagnosis DifferentialProstatemedicineHumansProstate diseaseAgedIntravascular large B-cell lymphomaKidneymedicine.diagnostic_testbusiness.industryProstateProstatic Neoplasmsmedicine.diseaseNon-Hodgkin's lymphomamedicine.anatomical_structureOncologyImmunohistochemistrybusinessKidney diseaseJournal of Clinical Oncology
researchProduct

Tumor necrosis factor (TNF) and lymphotoxin-a (LTA) polymorphisms and risk of non-hodgkin lymphoma in the interLymph consortium

2010

In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF -308G>A (rs1800629), lymphotoxin-alpha (LTA) 252A>G (rs909253), IL10 -3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-…

MaleEpidemiologyTNFGastroenterology0302 clinical medicineRisk Factorsimmune system diseaseshemic and lymphatic diseasesAged 80 and over0303 health scienceseducation.field_of_studyLymphoma Non-Hodgkinnon-Hodgkin lymphomaMiddle Aged3. Good healthInterleukin-10EuropeLTA030220 oncology & carcinogenesisFemaleLymphotoxin alphaAdultmedicine.medical_specialtyCanadaAdolescentTumor necrosis factorMeta- and Pooled AnalysesPopulationPolymorphism Single NucleotideWhite People03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Predisposition to Diseaseeducation030304 developmental biologyAgedMycosis fungoidesbusiness.industryTumor Necrosis Factor-alphaAustraliaInternational AgenciesInterLymph ConsortiumOdds ratiomedicine.diseaseUnited StatesNon-Hodgkin's lymphomaLymphomaCase-Control StudiesImmunologyMantle cell lymphomalymphotoxin-alphabusinessDiffuse large B-cell lymphoma
researchProduct

Mediastinal syndrome from plasmablastic lymphoma in human immunodeficiency virus and human herpes virus 8 negative patient with polycythemia vera: a …

2017

Background: Plasmoblastic lymphoma is a rare and aggressive subtype of diffuse large B cell lymphoma, which occurs usually in the jaw of immunocompromised subjects. Case presentation: We describe the occurrence of plasmoblastic lymphoma in the mediastinum and chest wall skin of an human immunodeficiency virus-negative 63-year-old Caucasian man who had had polycytemia vera 7 years before. At admission, the patient showed a superior vena cava syndrome, with persistent dyspnoea, cough, and distension of the jugular veins. Imaging findings showed a 9.7 × 8 × 5.7 cm mediastinal mass. A chest wall neoformation biopsy and ultrasound-guided fine-needle aspiration biopsy of the mediastinal mass allo…

MalePathologySettore MED/21 - Chirurgia ToracicaCase ReportSettore MED/15 - Malattie Del Sangue0302 clinical medicinePolycythemia veraPolycythemia VeraCase report; Fine-needle aspiration biopsy; Hematology; Rare clinical case; Thoracic surgery; Medicine (all)UltrasonographyMedicine(all)Rare clinical caseSuperior vena cava syndromeHematologymedicine.diagnostic_testMedicine (all)MediastinumMediastinumGeneral MedicineHematologyHerpesviridae InfectionsSyndromeMiddle AgedThoracic surgerymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisHerpesvirus 8 HumanPlasmablastic Lymphomamedicine.symptommedicine.medical_specialtyBiopsy Fine-NeedleMediastinal Neoplasms03 medical and health sciencesInternal medicineHIV SeronegativityBiopsymedicineHumansbusiness.industryThrombosisFine-needle aspiration biopsymedicine.diseaseLymphomaSettore MED/18 - Chirurgia GeneraleDyspneaCoughJugular VeinsbusinessDiffuse large B-cell lymphomaPlasmablastic lymphoma030215 immunology
researchProduct

Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for auto…

2007

A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 (90Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII…

Malemedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentImmunologyIbritumomab tiuxetanSalvage therapyAuthor Keywords:RadioimmunotherapyBiochemistryGastroenterologyAntibodies Monoclonal Murine-DerivedTRIAL Author InformationAutologous stem-cell transplantationRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineRefractory Diffuse Large B-Cell LymphomaHumansYttrium RadioisotopesY-90-ibritumomab tiuxetanHematologic toxicity KeyWords Plus:B-CELL LYMPHOMAAuthor Keywords:Radioimmunotherapy; Y-90-ibritumomab tiuxetan; Hematologic toxicity KeyWords Plus:B-CELL LYMPHOMA; LOW-GRADE; RADIOIMMUNOTHERAPY; INDOLENT; TRIAL Author InformationAgedCerebral HemorrhageAged 80 and overSalvage TherapyChemotherapybusiness.industryRemission InductionAntibodies MonoclonalCell BiologyHematologyRADIOIMMUNOTHERAPYINDOLENTmedicine.diseaseSurvival AnalysisLOW-GRADESurgeryTransplantationRituximabFemaleLymphoma Large B-Cell DiffusebusinessRituximabDiffuse large B-cell lymphomamedicine.drug
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment

2004

Primary hepatic lymphoma is a rare but well-defined lymphoma entity that often pursues an aggressive clinical course. Most cases have been described in hepatitis C virus (HCV)-related chronic liver disease patients. Although anthracycline-based chemotherapy has been reported to be highly effective, the best therapeutic strategy has not been defined yet. The prognosis is dismal especially in patients treated with chemotherapy alone or when an advanced liver disease is present. Herein, we describe a case of primary hepatic large B-cell non-Hodgkin’s lymphoma, in a patient with HCV chronic infection. After a minor response with eight cycles of CHOP chemotherapy, a complete and sustained remiss…

Malemedicine.medical_specialtyalpha-interferonHepatitis C virusAlpha interferonCHOPChronic liver diseasemedicine.disease_causeGastroenterologyLiver diseasehemic and lymphatic diseasesInternal medicineremission primary hepatic lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicinevirus infectionHumansUltrasonographyHematologybusiness.industryLymphoma Non-HodgkinLiver NeoplasmsRemission InductionInterferon-alphaHematologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLymphomaLong-lastingImmunologyLymphoma Large B-Cell Diffusehepatitis Cbusiness
researchProduct

Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.

2015

Abstract Background: Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported. Method: Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944,…

OncologyAdultMalemedicine.medical_specialtyEpidemiologyChronic lymphocytic leukemiamedicine.medical_treatmentFollicular lymphomaBiologyArticleBody Mass IndexYoung Adultimmune system diseasesRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseLymphangiogenesisAdiposityAgedRetrospective StudiesPolymorphism GeneticAbsolute risk reductionDNA NeoplasmMiddle Agedmedicine.diseaseObesityLymphomaCytokineOncologyIL1AImmunologyCytokinesFemaleLymphoma Large B-Cell DiffuseBody mass indexCancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
researchProduct